Device Trial Radar · NCT06368622
Evolve China PMCF Study
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Apr 24, 2024
Primary completion
Nov 2027
Study completion Aug 2031
Sponsor
- Lead sponsor
- Stryker NeurovascularPublic (SYK)
- Sponsor type
- Industry
- Collaborators
- Stryker (Beijing) Healthcare Products Co., Ltd
- First posted
- Apr 16, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.
Conditions
- Intracranial Aneurysm
Interventions
Surpass Evolve Flow Diverter SystemDevice
Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neurological death or disabling strokeTime frame: 12 months (-3/ +6 months) post-procedure
- 100% occlusion without significant parent artery stenosisTime frame: 12 months (-3/+6 months) post-procedure
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, China
Peking University Third Hospital
Beijing, China
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.